{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:00Z","timestamp":1790409240519,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02616","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T01:34:14Z","timestamp":1542245654000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies"],"prefix":"10.3389","volume":"9","author":[{"given":"Guido","family":"Lancman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Arinsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Jhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van","year":"2018","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2119\/2006-00082.Stevenson","article-title":"CD38 as a therapeutic target","volume":"12","author":"Stevenson","year":"2006","journal-title":"Mol Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de","year":"2011","journal-title":"J Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1182\/blood-2016-11-749432","article-title":"Daratumumab (anti-CD38) induces loss of CD38 on red blood cells","volume":"129","author":"Sullivan","year":"2017","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1006\/bbrc.1993.2416","article-title":"A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes","volume":"196","author":"Zocchi","year":"1993","journal-title":"Biochem Biophys Res Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1096\/fasebj.10.12.8903511","article-title":"Human CD38, a cell-surface protein with multiple functions","volume":"10","author":"Mehta","year":"1996","journal-title":"FASEB J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.clml.2017.09.002","article-title":"Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma","volume":"18","author":"Chari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bjhh.2017.09.003","article-title":"Transfusion management for patients taking an anti-CD38 monoclonal antibody","volume":"40","author":"Bub","year":"2018","journal-title":"Rev Bras Hematol Hemoter."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/tme.1250","article-title":"Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies","author":"Carreno-Tarragona","year":"2018","journal-title":"Transfus Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.tracli.2017.12.001","article-title":"Daratumumab: Therapeutic asset, biological trap!","volume":"25","author":"Deneys","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bjhh.2017.07.002","article-title":"Role of daratumumab in transfusion medicine: a must know entity","volume":"39","author":"Subramaniyan","year":"2017","journal-title":"Rev Bras Hematol Hemoter."},{"key":"B20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4103\/0973-6247.214358","article-title":"Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody","volume":"11","author":"Lin","year":"2017","journal-title":"Asian J Transfus Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4103\/GJTM.GJTM_42_17","article-title":"Daratumumab (Anti-CD38) interference with serological testing: an emerging challenge for blood banks in developing countries","volume":"2","author":"Setia","year":"2017","journal-title":"Global J Transfus Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion"},{"key":"B23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.21307\/immunohematology-2019-025","article-title":"Dithiothreitol treatment of red blood cells","volume":"33","author":"Bub","year":"2017","journal-title":"Immunohematology"},{"key":"B24","volume-title":"The Blood Group Antigen Factsbook.","author":"Reid","year":"2012"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/trf.14021","article-title":"Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/NEJMc1804751","article-title":"F(ab')2 fragments to overcome daratumumab interference in transfusion tests","volume":"379","author":"Selleng","year":"2018","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/trf.13174","article-title":"An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab","volume":"55","author":"Schmidt","year":"2015","journal-title":"Transfusion"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/trf.14144","article-title":"How do I work up pretransfusion samples containing anti-CD38?","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"key":"B31","first-page":"26A","article-title":"Daratumumab-derived anti-CD38 can be easily mistaken for clinically significant antibodies to Lutheran antigens or to Knops antigens [abstract]","volume":"55","author":"Velliquette","year":"2015","journal-title":"Transfusion"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/j.1537-2995.2012.03922.x","article-title":"Risks and adverse outcomes associated with emergency-release red blood cell transfusion","volume":"53","author":"Mulay","year":"2013","journal-title":"Transfusion"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02616\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T21:56:03Z","timestamp":1662414963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02616\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2018.02616"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02616","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]},"article-number":"2616"}}